Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

NCT02691871 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Lung Adenocarcinoma

Interventions

DRUG: Apatinib (250 mg/d) + Docetaxel (60 mg/m2)
DRUG: Apatinib (500 mg/d) + Docetaxel (60 mg/m2)
DRUG: Apatinib (750 mg/d) + Docetaxel (60 mg/m2)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]